Kif15-IN-1
(Synonyms: 2-[[(2S)-2-(1,4-二氢-2,4-二氧代-3(2H)-喹唑啉基)-3-甲基-1-氧代丁基]氨基]-4-甲基-5-噻唑羧酸乙酯) 目录号 : GC16603
Kif15-IN-1 是有丝分裂驱动蛋白家族成员 15 (Kif15) 的抑制剂，用于细胞增殖性疾病的研究。
Cas No.:672926-32-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kif15-IN-1, a potent Kif15 kinesin inhibitor; inhibits cellular proliferation in various tumor cell lines [1].
Kif15,also known as Kinesin-12 and HKLP2, is a motor protein expressed in all cells during mitosis and in postmitotic neurons undergoing axon growth [2]. Kif15 is a kinesin-related protein whose mitotic homologues are believed to crosslink and immobilize spindle microtubules.KIF15 is involved in maintaining bipolar microtubulespindle apparatusin dividing cells and shares redundant functions with KIF11 [3].
References:
[1]. Preparation of quinazolinediones as Kif15 kinesin inhibitors for treating cellular proliferative disorders. Pat. Appl. Publ. (2004), US 20040053948 A1 20040318.
[2]. Buster D W, Baird D H, Yu W, et al. Expression of the mitotic kinesin Kif15 in postmitotic neurons: implications for neuronal migration and development[J]. Journal of neurocytology, 2003, 32(1): 79-96.
[3]. Vanneste D, Takagi M, Imamoto N, et al. The role of Hklp2 in the stabilization and maintenance of spindle bipolarity[J]. Current Biology, 2009, 19(20): 1712-1717.
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.323 mL | 11.6149 mL | 23.2299 mL |
| 5 mM | 0.4646 mL | 2.323 mL | 4.646 mL |
| 10 mM | 0.2323 mL | 1.1615 mL | 2.323 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。